Business
Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as Chief Financial Officer
VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the appointment of Dr. David M. Kideckel, Ph.D., MBA, as Chief Financial Officer (CFO), subject to approval from the TSX Venture Exchange (“TSXV”). Dr. Kideckel brings nearly two decades of experience in li
About this update from Rakovina Therapeutics Inc
[{"type":"image","alt":"Rakovina Therapeutics Inc","displaySize":"","headline":null,"caption":"Rakovina Therapeutics Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/5f38052c45a7c766c8843075311b5e6b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8pDE_lHFFxIFLy74uLNlBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5f38052c45a7c766c8843075311b5e6b","width":300,"height":101}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the appointment of Dr. David M. Kideckel, Ph.D., MBA, as Chief Financial Officer (CFO), subject to approval from the TSX Venture Exchange (“TSXV”).","length":441,"tagName":"p"},{"type":"text","content":"Dr. Kideckel brings nearly two decades of experience in life sciences, capital markets, and corporate advisory, with a proven track record of assisting public and private healthcare companies scale their operations and unlock shareholder value. He is the Founder and Principal of the Kideckel Advisory Group Inc., which provides fractional CFO, Chief Business Officer (CBO), and capital markets services to TSX- and Nasdaq-listed companies, as well as private corporations. He also serves as a Partner at Siskos & Associates, who has been appointed to provide the Company with full back-office accounting services, including the preparation of financial information.","length":670,"tagName":"p"},{"type":"text","content":"Prior to his current roles, Dr. Kideckel served as Managing Director, Head of Life Sciences, and Senior Institutional Equity Research Analyst at ATB Capital Markets. His industry experience includes leadership positions at Johnson & Johnson Inc. and Alexion Pharmaceuticals (acquired by AstraZeneca PLC), where he supported strategic growth initiatives in drug development and commercialization.","length":399,"tagName":"p"},{"type":"text","content":"Dr. Kideckel holds a Ph.D. in Neuroscience and Statistics from the University of Toronto’s Institute of Medical Science and an MBA from the Rotman Sch...